Literature DB >> 23999581

Kidney cancer: predicting survival after targeted therapy for mRCC.

Melanie Clyne.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23999581     DOI： 10.1038/nrurol.2013.205

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  2 in total

1.  Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD phase 3 trial data.

Authors:  Charles Ferté; Serge Koscielny; Laurence Albiges; Laurence Rocher; Jean-Charles Soria; Roberto Iacovelli; Yohann Loriot; Karim Fizazi; Bernard Escudier
Journal:  Eur Urol       Date:  2013-08-15       Impact factor: 20.096

2.  Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy.

Authors:  Rana R McKay; Nils Kroeger; Wanling Xie; Jae-Lyun Lee; Jennifer J Knox; Georg A Bjarnason; Mary J MacKenzie; Lori Wood; Sandy Srinivas; Ulka N Vaishampayan; Sun-Young Rha; Sumanta K Pal; Frede Donskov; Srinivas K Tantravahi; Brian I Rini; Daniel Y C Heng; Toni K Choueiri
Journal:  Eur Urol       Date:  2013-08-15       Impact factor: 20.096
  2 in total
  1 in total

Review 1.  Prognostic Value of Serum Lactate Dehydrogenase in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.

Authors:  Jie Shen; Zhen Chen; Qianfeng Zhuang; Min Fan; Tao Ding; Hao Lu; Xiaozhou He
Journal:  PLoS One       Date:  2016-11-18       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.